Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer

Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer

ER-positive breast cancer patients do not usually respond to immunotherapy. In this phase II clinical trial, the authors report the safety and efficacy of combining vorinostat and pembrolizumab with tamoxifen in ER-positive breast cancers and provide evidence that T-cell exhaustion may serve as a po...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Manuela Terranova-Barberio, Nela Pawlowska, Mallika Dhawan, Mark Moasser, Amy J. Chien, Michelle E. Melisko, Hope Rugo, Roshun Rahimi, Travis Deal, Adil Daud, Michael D. Rosenblum, Scott Thomas, Pamela N. Munster
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2020
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/64f0fec706954f5c93dba4c047a3944a
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/64f0fec706954f5c93dba4c047a3944a

Ejemplares similares